<scp>LRRK2</scp> as a Potential Disease‐Modifying Target in Sporadic Parkinson's Disease
Year: 2025
Type: article
Language: en
Topic: Parkinson's Disease Mechanisms and Treatments
Authors and affiliations:
raw_author_name: Anthony E. Lang
raw_affiliation_strings: Morton and Gloria Shulman Movement Disorders Clinic, Toronto Western Hospital and Edmond J. Safra Program in Parkinson Disease University of Toronto  Toronto Ontario Canada
Morton and Gloria Shulman Movement Disorders Clinic, Toronto Western Hospital and Edmond J. Safra Program in Parkinson Disease, University of Toronto, Toronto, Ontario, Canada
raw_author_name: Robert A. Hauser
raw_affiliation_strings: Parkinson's Disease and Movement Disorders Center University of South Florida  Tampa Florida USA
Parkinson's Disease and Movement Disorders Center, University of South Florida, Tampa, Florida, USA
raw_author_name: Lorraine V. Kalia
raw_affiliation_strings: Division of Neurology, Department of Medicine, Tanz Centre for Research in Neurodegenerative Diseases University of Toronto  Toronto Ontario Canada
Krembil Research Institute, Toronto Western Hospital University Health Network  Toronto Ontario Canada
Morton and Gloria Shulman Movement Disorders Clinic, Toronto Western Hospital and Edmond J. Safra Program in Parkinson Disease University of Toronto  Toronto Ontario Canada
Division of Neurology, Department of Medicine, Tanz Centre for Research in Neurodegenerative Diseases, University of Toronto, Toronto, Ontario, Canada
Krembil Research Institute, Toronto Western Hospital, University Health Network, Toronto, Ontario, Canada
Morton and Gloria Shulman Movement Disorders Clinic, Toronto Western Hospital and Edmond J. Safra Program in Parkinson Disease, University of Toronto, Toronto, Ontario, Canada
raw_author_name: Bonnie Hersh
raw_affiliation_strings: Biogen Inc.  Cambridge Massachusetts USA
Biogen Inc., Cambridge, Massachusetts, USA
raw_author_name: Zdenek Berger
raw_affiliation_strings: Biogen Inc.  Cambridge Massachusetts USA
Biogen Inc., Cambridge, Massachusetts, USA
raw_author_name: Roy Llorens Arenas
raw_affiliation_strings: Biogen Inc.  Cambridge Massachusetts USA
Biogen Inc., Cambridge, Massachusetts, USA
raw_author_name: Coro Paisan‐Ruiz
raw_affiliation_strings: Biogen Inc.  Cambridge Massachusetts USA
Biogen Inc., Cambridge, Massachusetts, USA
raw_author_name: Kyle Fraser
raw_affiliation_strings: Biogen Inc.  Cambridge Massachusetts USA
Biogen Inc., Cambridge, Massachusetts, USA
raw_author_name: Danna Jennings
raw_affiliation_strings: Denali Therapeutics  South San Francisco California USA
Denali Therapeutics, South San Francisco, California, USA
raw_author_name: Jillian H. Kluss
raw_affiliation_strings: Denali Therapeutics  South San Francisco California USA
Denali Therapeutics, South San Francisco, California, USA
raw_author_name: Sarah Huntwork‐Rodriguez
raw_affiliation_strings: Denali Therapeutics  South San Francisco California USA
Denali Therapeutics, South San Francisco, California, USA
raw_author_name: Anastasia G. Henry
raw_affiliation_strings: Denali Therapeutics  South San Francisco California USA
Denali Therapeutics, South San Francisco, California, USA
raw_author_name: J. Timothy Greenamyre
raw_affiliation_strings: Pittsburgh Institute for Neurodegenerative Diseases and Department of Neurology University of Pittsburgh School of Medicine  Pittsburgh Pennsylvania USA
Pittsburgh Institute for Neurodegenerative Diseases and Department of Neurology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA